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Abstract
The scientific literature represents a rich source for retrieval of knowledge on associations between biomedical concepts
such as genes, diseases and cellular processes. A commonly used method to establish relationships between biomedical
concepts from literature is co-occurrence. Apart from its use in knowledge retrieval, the co-occurrence method is also well-
suited to discover new, hidden relationships between biomedical concepts following a simple ABC-principle, in which A and
C have no direct relationship, but are connected via shared B-intermediates. In this paper we describe CoPub Discovery, a
tool that mines the literature for new relationships between biomedical concepts. Statistical analysis using ROC curves
showed that CoPub Discovery performed well over a wide range of settings and keyword thesauri. We subsequently used
CoPub Discovery to search for new relationships between genes, drugs, pathways and diseases. Several of the newly found
relationships were validated using independent literature sources. In addition, new predicted relationships between
compounds and cell proliferation were validated and confirmed experimentally in an in vitro cell proliferation assay. The
results show that CoPub Discovery is able to identify novel associations between genes, drugs, pathways and diseases that
have a high probability of being biologically valid. This makes CoPub Discovery a useful tool to unravel the mechanisms
behind disease, to find novel drug targets, or to find novel applications for existing drugs.
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Introduction
A wealth of knowledge concerning the function of genes and
their role in biological processes is present in the biomedical
literature, embodied in full text articles or the Medline abstract
database. Various text mining approaches have been developed to
extract information on gene function from this body of literature
[1,2] and these have been successfully applied to annotate genes
and proteins [3–7] and the interpretation of experimental results
[8–14].
A common method to establish relationships between biome-
dical concepts such as genes and pathways is co-occurrence [15].
This method is built on the assumption that biomedical concepts
occurring in the same body of text are in some way biologically
related. Co-occurrence-based methods can also be used to
discover new, hidden relationships, assuming that if A and C
both are connected with B, A and C might also have a
relationship, even if there is no published relationship between A
and C (Figure 1). Swanson has provided a classic example in his
study in which he found that fish-oil intake is beneficial for patients
suffering from Raynaud’s disease, a finding that was confirmed
experimentally a few years later [16,17]. Hidden literature
relationships can be used to confirm a hypothesis about a
relationship between A and C in a so called closed discovery
process [18–20]. In this process the user provides the hypothesis
that A is related to C, which is then tested by mining the literature
for shared biomedical concepts (B) that support the hypothesis
(Figure 1). Hidden relationships can also be used to generate novel
hypotheses about a relationship between A and C, in a so-called
open discovery process [18,19,21–23]. In this process the user
provides a starting point A (e.g. a disease) and examines the
literature for hidden relationships with other biomedical concepts
(C; e.g. genes, drugs) that are bridged by intermediates (B) that
share co-occurrences with A and C (Figure 1).
The tools that are currently available for performing open
discovery experiments are often limited to certain biomedical
domains, have only limited number of keywords describing the
biomedical terms, or retrieve hidden relationships formed by
uninformative concepts, such as ‘‘in vitro’’ or ‘‘microarray’’ which
are biologically less interesting [19,22,24]. Moreover, a bottleneck
with all open discovery tools is to identify true, biologically
informative, hidden relationships from spurious hits.
In a previous paper we described CoPub [25], a database of co-
occurrences of ,250.000 keywords (including gene names and
symbols) in Medline abstracts. CoPub is a database in which the
statistical relevance of all co-occurrences is pre-computed, which
makes it possible to perform statistical analyses of the significance
of the retrieved hidden relationships between biomedical concepts.
In addition, CoPub contains several categories of controlled
vocabularies such as genes, drugs, or diseases etc. As such, this
database is ideally suited for use in the discovery of hidden
relationships.
PLoS Computational Biology | www.ploscompbiol.org 1 September 2010 | Volume 6 | Issue 9 | e1000943In this paper we describe CoPub Discovery, a method that uses
the CoPub database for the open and closed discovery of hidden
literature relationships. Statistical analysis of the results using
ROC curves show that with CoPub Discovery true hidden
relationships can be distinguished from true negatives. Application
of this method in open ended retrieval of hidden relations yielded
novel hypotheses about gene-disease, drug-disease and drug-
biological process relationships which were validated bibliogra-
phically. Moreover, we used CoPub Discovery to identify two
novel compounds that would interact with cell proliferation.
Experimental validation showed that these compounds dose
dependently inhibited T-cell proliferation.
Results
CoPub Discovery performance evaluation
As described above the challenge in the discovery of hidden
relationships is to robustly discriminate true, biologically relevant,
relationships (TP) from spurious, false positive hits (FP). We used
Receiver Operating Characteristic (ROC) curve analyses to
evaluate the ability of CoPub Discovery to distinguish TP from
FP hidden relationships using literature partitioning as described
in detail in the Materials and Methods section and outlined in
Figure 2. All the ROC curves had AUCs (Area Under the Curve)
higher than the AUC of the curve for no discrimination (Figure 3).
High AUC’s were obtained for all types of hidden relationships
and a wide range of combinations of settings for inclusion of the
intermediates. Re-running the analysis with alternative scoring
schemes, such as the average instead of the minimal R-scaled
scores between A and B, and B and C or using the average of only
the 5 top scoring intermediates or using drugs rather than genes as
intermediates yielded similar results (data not shown). As an
additional measure of performance of CoPub Discovery, we
calculated the time lag between the average publication date of all
A–B and B–C intermediates and compared this date with the date
of first appearance of A and C in the literature (Figure 4). The
average time lag was 6.5 years, which is an indication to which
extent discoveries can be accelerated when this type of hypothesis
generation is used.
Taken together, these results show that CoPub Discovery is a
robust method that can be applied to quickly detect a variety of
biologically relevant hidden relationships.
Case studies
After the formal validation with ROC curves we used CoPub
Discovery to study a number of cases in an open discovery
approach. We now used all Medline abstracts published beforeMay
1, 2007 to find hidden relationships between genes, pathways, drugs
and diseases. For each hidden relationship an inferred R-scaled
score (Ri) was calculated. The biological rationale of the hidden
relations with the highest Ri were studied in more detail using the
Figure 1. ABC-principle of hidden relationships in literature. Hidden relationships in literature between biomedical concepts (e.g., genes,
diseases, drugs), for which A and C have no direct relationship, but are connected indirectly via B-intermediates, can be analyzed in a closed discovery
or open discovery setting. The inferred R-scaled (Ri) score between A and C, which is a measure for the strength of a hidden relationship, is calculated
by summation of the R-scaled scores of the weakest links (i.e. lowest R-scaled score), divided by the number of intermediates.
doi:10.1371/journal.pcbi.1000943.g001
Author Summary
The biomedical literature is an important source of
knowledge on the function of genes and on the
mechanisms by which these genes regulate cellular
processes. Several text mining approaches have been
developed to leverage this rich source of information by
automatically extracting associations between concepts
such as genes, diseases and drugs from a large body of
text. Here, we describe a new method that extracts novel,
not yet recognized associations between genes, diseases,
drugs and cellular processes from the biomedical litera-
ture. Our method is built on the assumption that even if
two concepts do not have a direct connection in literature,
they may be functionally related if they are both
connected to an overlapping set of concepts. Using this
approach we predicted several novel connections be-
tween genes, diseases, drugs and pathways. Our results
imply that our method is able to predict novel relation-
ships from literature and, most importantly, that these
newly identified relationships are biologically relevant. Our
method can aid the drug discovery process where it can
be used to find novel drug targets, increase insight in
mode of action of a drug or find novel applications for
known drugs.
CoPub Discovery: A Literature-Based Discovery Tool
PLoS Computational Biology | www.ploscompbiol.org 2 September 2010 | Volume 6 | Issue 9 | e1000943Figure 2. CoPub Discovery validation by literature-partitioning. A literature-partitioning analysis was performed to evaluate CoPub
Discovery’s ability to filter true positive (TP) from false positive (FP) hidden relationships in literature. Abstracts published in the year 2000 up to May
1, 2007 were used to validate relationships inferred from abstracts published before the year 2000.
doi:10.1371/journal.pcbi.1000943.g002
Figure 3. CoPub Discovery statistical evaluation. Receiver Operating Characteristic (ROC) curve analyses were performed to statistically
evaluate the ability of CoPub Discovery to distinguish true positive (TP) from false positive (FP) hidden relationships in literature. In this figure, ROC
curves are shown of gene-disease, drug-disease and drug-biological process hidden relationship analyses for several intermediate inclusion criteria.
For each tested setting, the false positive rate was plotted against the true positive rate for each inferred R-scaled (Ri) score cutoff.
doi:10.1371/journal.pcbi.1000943.g003
CoPub Discovery: A Literature-Based Discovery Tool
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provided in the CoPub Discovery output.
Case study 1: Disease-gene hidden relationships. Graves’
disease (GD) is a complex autoimmune thyroid disorder, which is
characterized by hyperthyroidism (i.e. over-production of thyroid
hormones). Auto-antibodies against the thyroid-stimulating
hormone receptor were shown to be responsible for the
hyperthyroidism in GD [26]. The mechanisms behind the onset
of GD are not completely understood, but it is thought that the
development of GD depends on complex interactions among
environmental and genetic factors [27].
CoPub Discovery was used to identify genes that might play a role
in GD, but with no known relationship with GD. The analysis was
conducted allowing only genes as intermediates. Several genes were
f o u n di nl i t e r a t u r ew i t hah i d d e nr e l a t i o n s h i pw i t hG Dt h a th a daRi
s c o r ea b o v et h es i g n i f i c a n c ec u t o f f( T a b l e1 a ) .A tt h et o po ft h eg e n e
list, connected with 21 genes to GD, is Programmed cell death 1 (PDCD1).
PDCD1 is a cell surface receptor that regulates T-cell
proliferation and activation, which was linked in earlier studies
to autoimmune diseases like type 1 diabetes and rheumatoid
arthritis [28,29]. Genetic studies, published after May 1, 2007
(which was not used for constructing the relationship between
PDCD1 and GD) showed that small genetic effects within PDCD1
contribute to the development of GD [30,31], and confirms that
the proposed association between PDCD1 and GD by CoPub
Discovery is indeed biologically relevant. One of the genes that
was identified as an intermediate between PDCD1 and GD is
Figure 4. Time lag between prediction and first appearance of
hidden relationships in literature. The time lag between the data
needed for prediction of a hidden relationship and its actual assertion in
literature is plotted for 1000 hidden relationships. For each hidden
relationship, the average publication date of all A–B and B–C literature
appearances was calculated and compared with the date on which A
and C were first mentioned in the literature. Note: the data was derived
from the literature-partitioning analysis.
doi:10.1371/journal.pcbi.1000943.g004
Table 1. Prediction of novel relationships between biomedical concepts using the open discovery setting.
a) Graves’ Disease – Gene Hidden Relationships
Gene Intermediates Ri
Programmed cell death 1 (PDCD1) 21 34.3
CD74 molecule, major histocompatibility complex class II (CD74) 20 35.4
TAP binding protein (TAPBP) 19 34.4
CD8b molecule (CD8B) 18 34.6
CD84 molecule (CD84) 17 34.4
b) Milnacipran – Disease Hidden Relationships
Disease/disorder Intermediates Ri
Obsessive-Compulsive Disorder 7 37.3
Serotonin Syndrome 54 5 . 6
Serotonin Syndrome 54 5 . 6
Drug withdrawal symptoms 53 6 . 8
Tardive Dyskinesia 53 6 . 2
Attention Deficit Hyperactivity Disorder 5 35.4
c) Pitavastatin - Biological Process Hidden Relationships
Biological process Intermediates Ri
Monocyte Activation 26 36.0
Endothelial Cell Differentiation 25 37.2
Osteoblast Differentiation 22 36.6
Adipocyte Differentiation 22 36.0
Intracellular signalling Cascade 19 37.1
The following intermediate inclusion criteria were used to calculate the hidden relationships: minimal number of co-publications between keywords: at least 3; minimal
R-scaled score between keywords: at least 20; intermediates used: genes (A and B), and genes, pathways and biological processes (C); literature: till May 1, 2007. The
significance cutoff of Ri scores were set to a maximum false-positive rate of 0.1, which was set to 34 for disease-gene and drug-disease relationships, and set to 36 for
drug-biological processes hidden relationships, as calculated in the literature partitioning analysis (Figure 2).
doi:10.1371/journal.pcbi.1000943.t001
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CTLA4, like PDCD1, is a negative regulator of T-cell activation
[32], and polymorphisms in this gene are associated with the onset
of GD [33,34]. Studies report that CTLA4 and PDCD1 act as co-
inhibitors of T-cell proliferation and activation [35,36]. This
functional association between PDCD1 and CTLA4 explains the
relationship between PDCD1 and GD, and indicates that the
CoPub Discovery predicted association between PDCD1 and GD
was correctly identified based on biological knowledge.
Case study 2: Drug-disease hidden relationships. Milna-
cipran, a serotonin and noradrenalin reuptake inhibitor (SNRI), is a
regularly prescribed drug to treat depression [37]. SNRIs prevent the
reuptake of serotonin and noradrenalin by pre-synaptic cells, and
thereby increase the extracellular availability of serotonin and
noradrenalin to bind to post-synaptic receptors, which enhances their
biological effect [38].
Depression is often accompanied by chronic pain. Therefore,
antidepressants like milnacipran also become more widely applied
to treat chronic pain [39,40]. Serotonin and noradrenalin act as
key mediators in various biological processes, and therefore
SNRIs, due to their dual action of preventing reuptake of both
serotonin and noradrenalin, are used to treat a range of distinct
disorders.
We used CoPub Discovery to predict new applications for
milnacipran. Several disorders were found by CoPub Discovery
that had a significant, hidden relationship in literature with
milnacipran using genes as intermediates (Table 1b). The top
scoring disorder, connected with 7 gene intermediates, is obsessive
compulsive disorder (OCD).
OCD is a common chronic anxiety disorder that can have
disabling effects on both adults and children. OCD is character-
ized by recurrent obsessions and uncontrolled compulsions such as
repetitive behavioral or mental acts that are performed in response
to an obsession [41]. Marble-burying behavior in mice is
recognized as a model for OCD [42]. In this model, inhibition
of marble burying is correlated with reduction of anxiety, which
can be achieved by treatment with selective serotonin reuptake
inhibitors (SSRIs) [43]. Several studies have shown that in addition
to SSRIs, SNRIs are also promising drug candidates for treatment
of OCD [44,45]. Again, to validate the predicted association
between milnacipran and OCD, we inquired the literature from
May 1, 2007 until present for studies that report on a functional
relationship between milnacipran and OCD. Indeed, in a study
published after May 1, 2007, milnacipran was found to
significantly inhibit marble-burying behavior in mice [46], which
demonstrates that the inferred relationship between milnacipran
and OCD by CoPub Discovery appears biologically valid.
Two genes that connect milnacipran and OCD are the
norepinephrine transporter SLC6A2 and the serotonin transporter
SLC6A4 (Figure 5b). Milnacipran, SLC6A2 and SLC6A4 are
linked in literature by studies that report on the inhibitory effect of
milnacipran on norepinephrine and serotonin uptake [47,48],
whereas susceptibility to OCD was linked in literature to
polymorphisms in SLC6A4 and SLC6A2 [49,50]. These reports
underpin a functional relationship between milnacipran and
OCD, and shows that the predicted relationship between
milnacipran and OCD by CoPub Discovery can be well explained
by the biology of the intermediates.
Case study 3: Drug - biological process hidden
relationship. Pitavastatin is a new synthetic inhibitor of 3-
hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase,
which was shown to be a potent cholesterol-lowering agent [51].
The short-term and long-term lipid-modifying effects of
pitavastatin have already been investigated in subjects with
familial hypercholesterolemia, hypertriglyceridemia and type 2
diabetes mellitus [51], and the drug has been in Phase III trials in
Europe, US and Japan [52].
The primary effect of a drug on its target and on related cellular
processes is in many cases well known, whereas other beneficial,
pleiotropic effects are often less well understood or are not
immediately clear from literature. To predict additional cellular
effects of pitavastatin and to understand its mode of action, CoPub
Discovery was used predict relationships between biological
processes and pitavastatin using genes and biological processes
as intermediates.
It appeared that the four top scoring biological processes
represent cell differentiation processes (Table 1c). To assess
whether pitavastatin indeed affects cell differentiation, we
inspected the literature from after May 1, 2007 that report on
such an association. For adipocyte differentiation, indeed a direct
link between pitavastatin administration and cell differentiation
was reported [53]. In this study, pitavastatin was shown to have an
inhibitory effect on preadipocyte differentiation into mature
adipocytes by attenuating the expression of Peroxisome proliferator
activated receptor gamma (PPARc), a known inducer of adipogenesis
[54,55] and one of the intermediates in the hidden relationship
between pitavastatin and adipocyte differentiation. This indicates
that the predicted linkage between pitavastatin and adipocyte
differentiation by CoPub Discovery is very likely and merits
further research.
Pivastatin is connected to monocyte activation/differentiation
with 26 intermediates (Table 1c). Activation of monocytes induces
monocyte migration to sites of inflammation and induces
differentiation of monocytes into macrophages, dendritic cells
and osteoclasts [56,57]. Inspection of the intermediates identified,
among others, Chemokine (C-C motif) ligand 2 (CCL2, also known as
MCP1) and PPARc (Figure 5c). The literature that links monocyte
activation and differentiation to CCL2 and CCL2 to pitavastatin,
show that CCL2 is an inducer of monocyte activation and
migration [58] and that pitavastatin attenuates gene expression of
CCL2 in smooth muscle and endothelial cells [59,60]. This raises
the hypothesis that pitavastatin is able to block monocyte
activation and migration by downregulation of CCL2 gene
expression in CCL2-secreting cells.
Similarly, the literature shows that pitavastatin downregulates
the expression of PPARc in macrophages [61]. The expression of
PPARc is upregulated in activated monocytes/macrophages and
PPARc plays a role in induction of differentiation of macrophages
into foam cells [62], raising the possibility that by downregulating
PPARc expression, pitavastatin is able to suppress activation and
differentiation of monocytes into macrophages. The hypothesis
that pitavastatin is linked to cell differentiation is in line with
studies on simvastatin, which is also a HMG-CoA reductase
inhibitor, that was shown to affect cell differentiation [63,64].
Altogether, pitavastatin is strongly linked to cell differentiation
by CoPub Discovery. In cardiovascular disease, aberrant differ-
entiation of macrophages into foam cells leads to plaque formation
at vascular endothelium cells and can cause occlusion of blood
vessels [65], whereas over-abundance of adipocytes causing obesity
is considered to be a major risk factor for type II diabetes [66].
Although the beneficial effect of pitavastatin on atherosclerosis and
diabetes has been well recognized [51], the underlying mechan-
isms on how pitavastatin initiates these effects have remained
elusive. Based on the results of CoPub Discovery, it might be
hypothesized that pitavastatin might prevent foam cell formation
by blocking monocyte differentiation via suppression of CCL2 and
PPARc expression. Furthermore, the proposed relationship
between pitavastatin and adipocyte differentiation, which was
CoPub Discovery: A Literature-Based Discovery Tool
PLoS Computational Biology | www.ploscompbiol.org 5 September 2010 | Volume 6 | Issue 9 | e1000943Figure 5. Novel predicted relationships. Hidden relationships are visualized between a) Graves’ disease and Programmed cell death 1 (PDCD1), b)
milnacipran and obsessive-compulsive disorder, and c) pitavastatin and monocyte activation. A and C biomedical concepts are represented as red
circles (genes) or red squares (disease, drug or biological process), whereas B-intermediates are represented as blue circles (genes) and orange
squares (pathways and biological processes). The edges between nodes represent co-publications in Medline abstracts.
doi:10.1371/journal.pcbi.1000943.g005
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of pitavastatin on obesity and diabetes [66].
Taken together, the results of CoPub Discovery show that this
tool is well-suited to predict mechanisms of drug action and to
derive hypothesis about the biological pathways that are involved.
Case study 4: Biological process - drug hidden
relationship. To experimentally test a number of predicted
relationships we used CoPub Discovery to search for drugs that
could interfere with cell proliferation, a process for which assays
are readily available. Several drugs were found to have a
significant hidden relationship when using genes as intermediates
with the term ‘cell proliferation’ (Table 2). From this list, two top-
scoring compounds; dephostatin, a protein tyrosine phosphatase
inhibitor [67], and damnacanthal, a protein tyrosine kinase
inhibitor [68], were selected to test their hypothesized
association with cell proliferation in an in vitro cell assay.
Human peripheral blood mononuclear cells (PBMCs) were pre-
incubated with damnacanthal or dephostatin for concentrations
ranging from 0.01 to 10 mM, followed by incubation with CD3/
CD28 antibodies, which triggers T lymphocyte proliferation. Both
damnacanthal and dephostatin inhibited proliferation of PBMCs
for concentrations in the mM-range, with EC50’s of 2.67 mMa n d
1.96 mM respectively (Figure 6). Cell viability and apoptosis were
not affected by damnacanthal and dephostatin indicating that
damnacanthal and dephostatin specifically inhibit cell proliferation.
An earlier study showed that damnacanthal inhibits Ras
function [69], which provides a mechanism of action of how
damnacanthal might influence cell proliferation, as Ras oncogenes
are involved in cell cycle regulation. A study performed prior May
2007 showed that dephostatin inhibits the growth of Jurkat cells
[70], therefore it can be argued that the inhibitory effect of
dephostatin on cell proliferation was already known. However the
term ‘cell proliferation’ was not mentioned in the abstract of this
paper and therefore CoPub Discovery qualified the relationship
between dephostatin and ‘cell proliferation’ as novel.
These experiments provide evidence that the predicted hidden
relationships with CoPub Discovery of damnacanthal and
dephostatin with cell proliferation were indeed correct.
Discussion
In this paper we described CoPub Discovery, a web-based tool
that mines the Medline database for novel relationships between
genes, diseases, drugs and pathways. The results show that using
hidden relationships, we can successfully identify novel disease-
related genes, generate novel hypotheses on drug mode of action
and predict novel lead compound applications.
Drug discovery is a difficult and time-consuming process.
Despite the strong increase in funding of research and develop-
ment the last decade, the number of drugs that reach the market
each year is lagging behind [71]. Several strategies have been
adopted to bridge this gap. The use of systems biology for gaining
better knowledge on the mechanisms of drug action and toxicity
[72–75] and the use of biomarkers that are predictive for a certain
biological outcome [76–78], are widely used solutions to improve
decision making. In addition, drug repositioning, which is the use
of existing drugs for new applications, is another area that is
gaining much attention as a means to boost drug development
[79]. Several text mining solutions have been developed to assist in
and speed up the above strategies.
In a recent paper, Compillos et al. showed how text mining of
drug labels, can be used to infer whether two drugs share the same
target [80]. Our study identified several novel targets for known
drugs, based on a different algorithm and another text corpus.
This indicates that mining of literature is an interesting and fruitful
approach to identify new drug-target relations, a first step in
developing drugs towards new applications.
Detailed knowledge of the mechanism of action of a drug and
the biological processes that are targeted by a drug is of
importance for fine tuning drugs and biomarker discovery. In an
earlier study, we showed that the application of text mining on
expression data from a toxicogenomics experiment yielded
detailed insight in the mode of toxicity of the tested compounds
[13]. With the hidden relationship algorithm presented in this
paper we provide a text mining tool that is independent of gene
expression data, to improve the understanding of a drug’s
mechanism of action and the pathways targeted by that drug.
Table 2. Prediction of novel links between cell proliferation
and drugs using open discovery.
Drug Name # Intermediates Ri
Dephostatin 22 36.8
Damnacanthal 15 37.2
Aniracetam 14 36.4
Mizolastine 12 36.2
Betaseron 12 36.2
The following intermediate inclusion criteria were used to calculate the hidden
relationships: minimal number of co-publications between keywords: at least 2;
minimal R-scaled score between keywords: at least 20; intermediates used:
genes; literature: till May 1
st 2007. The significance cutoff of Ri scores were set to
a maximum false-positive rate of 0.1, which was set to 36 for the used settings,
as calculated in the literature partitioning analysis (Figure 2).
doi:10.1371/journal.pcbi.1000943.t002
Figure 6. In vitro cell proliferation assay validates CoPub
Discovery’s prediction. The predicted influence of damnacanthal
(red line and bullets) and dephostatin (blue line and triangles) on cell
proliferation was tested in an in vitro cell assay. For both damnacanthal
and dephostatin, the percentage of inhibition was measured and
plotted against compound concentration. Both compounds were
shown to inhibit cell proliferation in PBMCs when using concentrations
in the 1 to 10 mM-range. The EC50 was estimated at 1.96 mM for
dephostatin and for damnacanthal at 2.67 mM.
doi:10.1371/journal.pcbi.1000943.g006
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biologically relevant relationships in literature, several improve-
ments may be envisioned. For example, incorporation of
additional evidence for true relationships between concepts from
sources other than literature, such as protein-protein interaction
data or gene co-expression data, could help prioritize relationships
by biological relevance. Furthermore, an additional measure of
confidence could come from analyzing the relationships between
the intermediates that connect A and C. A highly interconnected
set of intermediates could indicate/validate higher biological
relevance compared to a set with few interconnections.
Co-occurrence-based text mining does not capture the type of
the extracted relationships (e.g. A binds, blocks, induces B).
Therefore, in the CoPub Discovery web server the results are
linked to the original abstracts in which the relationships were
found. This enables the scientist to read the facts to uncover the
type of relationship between A and C. A good starting point for
discovery would be to look for intermediate nodes (B) that have the
highest R-scaled scores for both node A and node C, because they
have the strongest link between A and C. After selecting a few of
these nodes, the researcher can perform a detailed analysis on the
functional association between A and C by reading the abstracts in
which A and B, and B and C are mentioned. Additionally,
incorporation of natural language processing in hidden relation-
ship analysis could assist in determining the type and direction of
the relationship between A and C.
In the validation procedure of CoPub Discovery using ROC
curve analysis we define FPs as A–C relationships that are
predicted in the literature before the year 2000 that were not
detected in subsequent literature. It might be well true that a FP is
in fact a novel discovery, but is not yet discovered in subsequent
literature. Furthermore, one can argue that a high area under the
curve (AUC) score indicates that CoPub Discovery discovers very
little that would not have been eventually discovered without it. In
this respect, the 6.5 year time lag between the CoPub Discovery
and the report in literature may be more indicative of the true
value of CoPub Discovery; it significantly speeds up hypothesis
generation, filtering and testing as was demonstrated in case
example 4 in which we exactly followed this approach.
Evaluating the ROC curves in light of the performance of other
text mining tools is hampered by the fact that not all of the tools
are accessible or work on different text corpora or use different
thesauri. Development of tools for discovery of hidden relation-
ships would benefit from the use of expert-curated test and training
sets on well-defined literature corpora, as is done in the
BioCreative text mining challenges.
The statistical underpinning of CoPub Discovery provides a
significant advantage over existing text mining tools applied in the
area of drug development [19,22,24]. It allows confidence level
calculations for hidden relationships and facilitates the discrimina-
tion of biologically relevant from biologically less interesting
hidden relationships. To ensure the quality of the hidden
relationships, several stringencies were placed on the biomedical
concepts used in CoPub Discovery. For example, the biomedical
concepts used in literature mining were all pre-tested for false
positive generation upon inclusion in one of the biomedical
concept thesauri. Furthermore, only genes and biological processes
are allowed as intermediates, which avoid relationships being
formed by non-informative concepts, such as ‘protein’, ‘cell assay’,
etc.
In short, the results in this paper show that CoPub Discovery is
able to identify novel associations between genes, drugs, pathways
and diseases that have a high probability of being biologically
valid. The fact that this is done rapidly, in an automated way,
makes the tool especially useful in areas where large amounts of
data need to be analyzed. A typical use of this tool could be to
quickly rank potential new biomarkers obtained from e.g. a
microarray experiment, based on their relation to diseases and
drugs. CoPub Discovery could also help in drug repositioning in
which list of drugs are clustered and ranked on basis of their
relation with diseases and biological processes of interest.
Materials and Methods
Text mining Medline abstracts
Six thesauri containing human genes, Gene Ontology biological
processes, liver pathologies, diseases, pathways and drugs were
used to search Medline XML files containing title, abstract and
substances (1966 – August 2009, http://www.nlm.nih.gov/bsd/
licensee/2009_stats/baseline_doc.html), as described previously
[13,25]. The keyword thesauri are based on biological items,
which represent an instance of a biological concept (e.g., a gene, a
pathway), and may contain multiple keywords (e.g., a gene is
assigned a full gene name, a gene symbol and gene aliases).
Typical full gene names contain commas and often additional
descriptions in parenthesis, which makes a full gene name an
inadequate direct search term. Therefore, full gene names were
processed by deleting all terms included in parentheses and allow a
white space for each comma in the full name. Two-letter gene
symbols and aliases were removed from the thesaurus and all other
gene symbols were compared to an English dictionary to remove
common English words (such as ‘‘AND’’, ‘‘CELL’’, etc.).
Regular expressions were used to search the compiled Medline
text files for the presence of all keywords (,250.000) from the
biological concept thesauri. For the full gene name descriptions the
characters "] [.-)(,:;" and space were allowed preceding and
following the full gene name and also an optional ‘‘s’’ was
permitted to follow the full gene name. Any white space in the full
gene name was allowed to be a white space or a dash. The same
regular expressions were applied to the non-gene biomedical
concept descriptions (e.g. diseases, biological processes).
Keywords that generated a hit in a Medline abstract were
stored, together with the PubMed identifiers (IDs) of the Medline
records in which the hit occurred. For every biological item the
hits were made non-redundant (note: multiple keywords of a
biological item can occur in the same Medline abstract), resulting
in a PubMed ID-biological item list. Gene symbol hits were
examined for ambiguity. This was done by matching words of the
full gene name in the abstract in which the gene symbol had a hit.
When parts of the full gene name matched in the abstract, the
gene symbol hit was regarded as a true positive; otherwise the gene
symbol hit was discarded. The performance of the thesaurus-based
keyword matching algorithm including the symbol disambiguation
step was evaluated by repeating the human gene normalization
task of the BioCreative II contest (www.biocreative.org). CoPub
reached a recall of 0.78 and a precision of 0.68, resulting in an F-
measure of 0.73. Based on this F-measure, CoPub would have
been ranked 11
th out of 21 participants [81].
Co-publication of biological items (e.g. a gene with a biological
process) was retrieved from the database by matching Medline
abstract occurrences. An R-scaled score ranging from 1–100,
which describes the strength of a co-citation between two
biological items given their individual frequencies of occurrence,
was used to assess the significance of a co-occurrence [15]. The R-
scaled score is based on the mutual information measure (MIM)
and was calculated as S=PAB/PA*PB in which PA is the number of
hits for biological item A divided by the total number of PubMed
IDs, PB is the number of hits for biological item B divided by the
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occurrences between biological item A and biological item B
divided by the total number of PubMed IDs. The relative score R
is produced as a log10 conversion of S (R=
10log S) and the 1–100
scaled-log-transformed relative score (R-scaled score) as R’=1+
99 * (R – Rmin)/(Rmax –R min), where Rmin and Rmax are the
lowest and highest R values present in the biological item co-
publication list, respectively. A high R-scaled score indicates that if
two biological concepts occur in literature they are often published
together, this in contrast to a low R-scaled score which indicates
that two biological concepts often occur separately in literature
and less often together. Based on previous experiences using
CoPub for the interpretation of microarray data, an R-scaled score
of above 40 can be regarded as biologically significant.
The scoring of hidden relationships between biomedical
concepts was adapted from Wren’s minimal MIM (MMIM)
model [82] where we used an R-scaled score instead of a MIM
score. The strength of the hidden relationship between A and C is
calculated using the R-scaled scores between A and B, and
between B and C. This inferred R-scaled (Ri) score between A and
C is calculated by summation of the R-scaled scores over the
intermediates B, taking the lowest score in each pair (AB, BC), and
dividing by the number of intermediates (Figure 1).
Bibliographic prediction and validation by literature
partitioning
Medline was divided into two sets (Figure 2). One set, the
background set, contained abstracts published before the year
2000. The second set, the test set, contained abstracts published
from the year 2000 up to May 1, 2007. Biomedical concept pairs
were formed from the background set, using the following criteria:
1) The members of the pair do not co-occur in any abstract. 2)
Each member of the pair occurs in at least 10 distinct abstracts. 3)
The members share at least 5 intermediates.
The test set was then used to evaluate whether the pairs from
the background set had a true relationship or not. A true
relationship for a pair (TP) was defined using the following criteria:
1) The pair should have at least 3 co-occurrences in the test set. 2)
The R-scaled score for this pair should be .40. All other pairs (FP)
were regarded as not having a true relationship. CoPub Discovery
was then evaluated for the ability to predict TPs from the
background set.
To this end an inferred R-scaled (Ri) score was calculated for
each pair of the background set and the performance of CoPub
Discovery of separating TP from FP relationships was measured
with ROC curves generated by varying the Ri threshold. The area
under the curve (AUC) of the ROC curve is equal to the
probability that a method will rank a randomly chosen positive
instance higher than a randomly chosen negative one [83].
To allow comparison of CoPub Discovery with other literature-
based discovery tools we have made the validation data of CoPub
Discovery (ROC curve analyses) available in supplementary Table
S1. Furthermore, we provide a web service with which the thesauri
and publication data can be downloaded. The web server and web
service implementation of the method described in this paper,
CoPub Discovery, is available at http://www.copub.org.
In vitro cell proliferation, viability and apoptosis assays
Damnacanthal (3-Hydroxy-1-methoxyanthraquinone-2-alde-
hyde), Merck Biosciences, Cat.No. 251650. 3,4-Dephostatin
(3,4-Dihydroxy-N-methyl-N-nitrosoaniline), Merck Biosciences,
Cat.No. 263202. Cell proliferation assays were performed with
human peripheral blood mononuclear cells (PBMCs), stimulated
with CD3 (OKT3)/CD28 (pelicluster CD28 clone CLB-CD28/1,
Sanquin, the Netherlands) antibodies at a concentration of 125
ng/ml and 250 ng/ml respectively in the presence or absence of
compounds. Proliferation was determined after 3 days via
3H-
thymidin incorporation for 24 hours. Viability of PBMCs was
measured by Alamar Blue cell viability assay (Molecular Probes/
Invitrogen, Eugene, OR). Apoptosis of PBMCs was measured
using caspase GLO 3/7 activity assay (Promega, Madison, WI).
Supporting Information
Table S1 ROC curve data used to validate CoPub Discovery -
This supplementary table contains the raw data of the ROC curve
analysis to validate CoPub Discovery for Disease-Gene, Drug-
Disease and Drug-Biological Process hidden relationships, for
several B-node inclusion criteria. The true positive rate (TPR) was
calculated as: TPR=TP/TP+FN, and the false positive rate (FPR)
was calculated as: FPR=FP/FP+TN (TP=True positive,
FN=False negative, FP=False positive and TN=True negative).
Found at: doi:10.1371/journal.pcbi.1000943.s001 (0.17 MB XLS)
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